From: Ocular gene transfer in the spotlight: implications of newspaper content for clinical communications
Timeline estimate | Predicted year for outcome | Outcome | Source |
---|---|---|---|
“Bennett, an associate professor of ophthalmology at the University of Pennsylvania…said she hopes initial experiments in people can begin within about two years.” | 2003 | Leber congenital amaurosis clinical trials began in 2007, with phase-I results published in 2008 (Bainbridge et al.,[6]; Hauswirth et al.,[7]; Maguire et al.,[8]). | Anonymous: Gene therapy restores dogs’ eyesight, may treat blind. Houston Chronicle; 2001, April 28. |
“Within five years [gene transfer] could be ready for testing on people who suffer age-related macular degeneration.” | 2013 | Phase I clinical trials were initiated in 2010 (NCT01678872). | Highfield R: Hope of genetic cure for failing eyesight. |
The Daily Telegraph; 2008, April 28. | |||
“This [phase-I gene transfer clinical trial for Leber congenital amaurosis] really paves the way for developing a treatment for people who have so far had no prospect of a cure,” said Robin Ali, an ophthalmologist at UCL… “Within two to three years it might be approved for use in the clinic.” | 2010-2011 | Leber congenital amaurosis is currently recruiting for a phase-III clinical trial (NCT00999609). | Sample I: Maze walk marks ‘huge advance’ in gene therapy for blindness. The Guardian; 2008, April 28. |
“[achromatopsia] treatment could be as little as four or five years away.” | 2016-2017 | To be determined. | Hilpen K: The boy who sees in black and white. The Daily Express; 2012, March 6. |